𝔖 Bobbio Scriptorium
✦   LIBER   ✦

High-dose dexamethasone for refractory or relapsing multiple myeloma

✍ Scribed by William R. Friedenberg; Robert A. Kyle; William H. Knospe; John M. Bennett; Anastasios A. Tsiatis; Martin M. Oken

Publisher
John Wiley and Sons
Year
1991
Tongue
English
Weight
464 KB
Volume
36
Category
Article
ISSN
0361-8609

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

High-dose liposomal daunorubicin and hig
High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia
✍ Jorge Cortes; Elihu Estey; Susan O'Brien; Francis Giles; Yu Shen; Charles Koller πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 89 KB πŸ‘ 1 views

## Background: Liposomal encapsulation of daunorubicin (daunoxome, dnx; nexstar pharmaceutical, boulder, co) changes the pharmacology profile to increase delivery to tumor sites and decrease toxicity. the authors investigated the effect of daunorubicin in combination with ara-c in patients with ref

High serum lactate dehydrogenase level p
High serum lactate dehydrogenase level predicts short survival after vincristine–doxorubicin–dexamethasone (VAD) salvage for refractory multiple myeloma
✍ Miyuki Suguro; Yshinobu Kanda; Rie Yamamoto; Aki Chizuka; Tamae Hamaki; Tomohiro πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 34 KB

We evaluated possible prognostic factors just before salvage therapy with vincristine, doxorubicin, and dexamethasone (VAD) for 36 patients with refractory multiple myeloma. The median duration from diagnosis to the first VAD salvage was 14 months (range 2-76 months). Among parameters that have been